Here is a concise 5-mark short note on schizophrenia:
Schizophrenia
Definition
Schizophrenia is a chronic, severe psychotic disorder characterized by disturbances in thought, perception, emotion, and behavior. It has a lifetime prevalence of slightly less than 1%, with peak onset in late adolescence to early adulthood (slightly earlier in males than females).
Etiology / Pathogenesis
The exact cause is unknown, but the following factors are recognized:
- Genetic factors - account for up to 50% of risk; multiple gene loci are involved
- Neurotransmitter hypothesis - dopamine hyperfunction in subcortical (mesolimbic) pathways underlies positive symptoms; dopamine hypofunction in the prefrontal cortex (mesocortical pathway) underlies negative/cognitive symptoms. Glutamatergic dysfunction also contributes.
- Neurodevelopmental factors - subtle disruptions in cortical cytoarchitecture (a nongliotic neuropathologic process) are found on postmortem studies
- Psychosocial stressors - can precipitate exacerbations and worsen the course
Clinical Features
Symptoms are classified into three groups:
| Type | Examples |
|---|
| Positive symptoms (excess/distortion) | Delusions, hallucinations (auditory most common), disorganized speech, bizarre behavior |
| Negative symptoms (deficit) | Affective flattening, abulia (lack of will), apathy, alogia, social withdrawal |
| Cognitive symptoms | Impaired attention, working memory, executive function |
Diagnosis (DSM-5 Criteria)
Two or more of the following for at least 1 month, with overall disturbance lasting 6 months, causing impaired functioning:
- Delusions
- Hallucinations
- Disorganized speech
- Grossly disorganized or catatonic behavior
- Negative symptoms
Medical, neurological, and substance-related causes must be excluded (e.g., autoimmune encephalitis can mimic a first psychotic episode).
Treatment
1. Antipsychotic medications (mainstay)
- First-generation (typical): Chlorpromazine, haloperidol - effective for positive symptoms; limited by extrapyramidal side effects (EPS) and tardive dyskinesia
- Second-generation (atypical): Risperidone, olanzapine, quetiapine - fewer EPS, less prolactin elevation; associated with metabolic syndrome and weight gain
- Clozapine - greatest efficacy (especially treatment-resistant cases); requires monitoring for agranulocytosis
2. Adjunctive therapies
- Benzodiazepines for acute agitation
- Long-acting injectable antipsychotics to reduce relapse rates
3. Psychosocial rehabilitation - assertive community treatment, cognitive behavioral therapy, vocational rehabilitation; early use at onset improves long-term outcomes
Key points to remember for 5 marks:
- Chronic psychotic illness, <1% prevalence
- Dopamine (D2) hypothesis - positive vs. negative symptoms linked to different pathways
- DSM-5: ≥2 symptoms for 1 month, total duration ≥6 months
- Atypical antipsychotics are now first-line; clozapine for refractory cases
- Psychosocial rehabilitation is essential alongside pharmacotherapy
(Sources: Goldman-Cecil Medicine, 27th ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th ed.)